Browse by Audience
Skip to content
Papers of the Week
Efficacy of high dosage anti-inflammatory EPA/DHA for migraine prophylaxis: a network meta-analysis.
Authors
Tseng PT, Zeng BY, Chen JJ, Kuo CH, Zeng BS, Kuo JS, Cheng YS, Sun CK, Wu YC, Tu YK, Stubbs B, Carvalho AF, Liang CS, Chen TY, Hsu CW, Suen MW, Yang CP, Hsu SP, Chen YW, Shiue YL, Hung CM, Su KP, Lin PYAbstract
Migraine is a highly prevalent neurological disorder, with prevalence rates ranging from 9% to 18% worldwide. Current pharmacological prophylactic strategies for migraine have limited efficacy and acceptability, with relatively low response rates of 40%-50% and limited safety profiles. Eicosapentaenoic acid (EPA)/docosahexaenoic acid (DHA) are considered to be promising therapeutic agents for migraine prophylaxis.